The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 279 participants.
Also called NCT03599284
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 279 participants
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Registry
-
NCT03599284
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03599284. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-30 (actual); primary completion 2019-06-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
- Condition
- Coronary Artery Disease
- Condition
- Percutaneous Coronary Intervention
- Condition
- Platelet Aggregation Inhibitors
- Intervention (Drug)
- Vicagrel 5mg
- Intervention (Drug)
- Vicagrel 6mg
- Intervention (Drug)
- Vicagrel 7.5mg
- Intervention (Drug)
- Clopidogrel 75mg
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Record details
- Record id
cardio:ct-nct03599284- Content hash
3ebd7f49b7cb5a031e4c45d58661f02e55bfe25acd2d23e533db5a33bcfc2717